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The following abstract is part of an ongoing series of
articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases,
which is part of the Cochrane Collaboration. The
review is published in full on The Cochrane Library,
a quarterly electronic journal available on CD-ROM
and via the Internet. The electronic format allows
Cochrane reviews to accommodate new data as they
become available, making the library a consistently
up-to-date source of information over time.
Certain abstracts appearing on the Cochrane
Library may be presented in a simpler, less scientific
format than the abstract presented here to permit
greater accessibility to the public. However, the sub-
stance of both versions is the same. Cochrane reviews
are now indexed on MEDLINE.
If you are interested in writing a Cochrane review or
contributing to the activities of the Cochrane Peri-
pheral Vascular Diseases Group please contact:
Professor FGR Fowkes,
Cochrane Collaborative Review Group on Peripheral
Vascular Diseases,
Public Health Sciences University of Edinburgh,
Teviot Place, Edinburgh EH8 9AG,
Tel:  44 (0) 131 650 3220,
Fax:  44 (0) 131 650 6904.
Any comments or criticisms on Cochrane
reviews/abstracts should be made through the
comments/criticisms facility on the Cochrane Library,
or by contacting the group at the above address.
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Elevated plasma levels of the amino acid homocys-
teine (hyperhomocysteinaemia) are associated with
atherosclerosis. In addition, there is a poorer progno-
sis, both in the progression of the disease and outcome
after therapy. Treatment to lower homocysteine levels
has been shown to be both effective and cheap in
healthy volunteers. However, the impact of reducing
homocysteine levels on the progression of atheroscler-
osis and patency of vessels after treatment for athero-
sclerosis is still unknown and forms the basis for this
review.
Objectives
To assess the effects of plasma homocysteine-lowering
therapy on the clinical progression of disease in
patients with peripheral arterial disease and hyper-
homocysteinaemia, including, as a subset, those
who have undergone surgical or radiological
intervention.
Search Strategy
The reviewers searched the Cochrane Peripheral
Vascular Diseases Group trials register, the Cochrane
Controlled trials register (2002, Issue 1), MEDLINE,
EMBASE and reference lists of relevant articles.
Selection Criteria
Randomised trials of the treatment of hyperho-
mocysteinaemia in patients with peripheral arterialience Ltd.
Cochrane Review Abstracts 399disease, before and after surgical or radiological
intervention versus no treatment for hyperho-
mocysteinaemia.
Data Collection and Analysis
The reviewers independently assessed trial quality
and extracted data. Information on adverse events
was collected from the trials.Main Results
There are currently no available trials on the treatment
of hyperhomocysteinaemia in patients with peripheral
arterial disease.
Reviewers' Conclusions
Well constructed trials assessing the impact of the
treatment of hyperhomocysteinaemia in patients
with peripheral arterial disease are urgently required.Eur J Vasc Endovasc Surg Vol 24, November 2002
